Petros Family Wealth LLC Has $228,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Petros Family Wealth LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 459 shares of the medical research company’s stock after buying an additional 36 shares during the quarter. Petros Family Wealth LLC’s holdings in Thermo Fisher Scientific were worth $228,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Cypress Advisory Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $253,000. Intact Investment Management Inc. increased its position in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock worth $1,353,000 after acquiring an additional 660 shares during the period. Purkiss Capital Advisors LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $1,121,000. LaFleur & Godfrey LLC increased its position in Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after acquiring an additional 2,488 shares during the period. Finally, Deutsche Bank AG increased its position in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after acquiring an additional 114,277 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.6%

TMO opened at $400.26 on Tuesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a market capitalization of $151.09 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 2.10 and a beta of 0.78. The company’s 50 day moving average price is $411.66 and its two-hundred day moving average price is $486.42.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. The company’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Citigroup lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Finally, Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.